For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors after progression on everolimus
The purpose of this study is to learn if treatment with a drug called cabozantinib to prevent tumor growth is better, the same, or worse than placebo (a pill that contains no active drug).
DiagnosisNeuroendocrine tumors of the pancreas and carcinoid tumors of the GI tract, lung, or other carcinoid tumors.
Must have had at least one prior therapy that included the drug everolimus.
Disease cannot be surgically resectable.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1: Will take cabozantinib tablets by mouth once daily.
- Group 2: Will take placebo tablets by mouth once daily.
- Quality of life questionnaires
- Optional blood and tissue collection for known and unknown future research.
Patients that have cancer growth will be followed every 6 months for survival until 8 years after starting the study.
If therapy is discontinued for reasons other than cancer growth, exams and imaging should be performed every 12 weeks until your cancer grows or start of a new cancer treatment.
For more information, visit ClinicalTrials.gov